Positive pivotal data for Trophos’ olesoxime in SMA; filings up next
By Jennifer Boggs
Monday, March 10, 2014
Patients with spinal muscular atrophy (SMA) and their families, who rejoiced two weeks ago when Isis Pharmaceuticals Inc. posted positive phase Ia/IIb data with its antisense candidate, got even better news Monday: French biopharma Trophos SA scored positive pivotal results with neuroprotective candidate olesoxime, putting it on track to file what could become the first treatment specifically for SMA.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.